GenSight Biologics S.A. (0RIM.L)

0,3850 -0,0250 (-6,10%) Alla chiusura: 02:09PM BST

GenSight Biologics S.A.

74, rue du Faubourg Saint-Antoine
Paris 75012
France
33 1 76 21 72 20
https://www.gensight-biologics.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 16

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Ms. Laurence Rodriguez	CEO & Director	N/D	N/D	1968
Dr. Jose-Alain Sahel M.D., Ph.D.	Scientific Founder, Vice Chairman of Scientific Advisory Board & Board Observer	N/D	N/D	N/D
Prof. Botond Roska M.D., Ph.D.	Scientific Founder & Chairman of Scientific Advisory Board	N/D	N/D	N/D
Dr. Luk H. Vandenberghe M.D., Ph.D.	Scientific Founder & Member of Scientific Advisory Board	N/D	N/D	N/D
Dr. Serge Picaud Ph.D.	Scientific Founder & Member of Scientific Advisory Board	N/D	N/D	N/D
Dr. Constance L. Cepko Ph.D.	Scientific Founder & Member of Scientific Advisory Board	N/D	N/D	N/D
Mr. Ivan Tortet	Interim Chief Financial Officer	N/D	N/D	1966
Mr. Scott Jeffers	Chief Technical Officer	N/D	N/D	N/D
Dr. Barrett Katz CMO, M.B.A., M.D.	Consultant	N/D	N/D	1951
Dr. Magali Taiël M.D.	Chief Medical Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative retinal diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. It has license agreements with Sorbonne Université, CNRS, Inserm and SATT Lutech; Inserm Transfert S.A, Genethon, and Harvard; Massachusetts Institute of Technology; Novartis Pharma AG; Sorbonne University, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale and Satt Lutech; Association Française contre les Myopathies, Inserm Transfert S.A; and non-exclusive license agreement with Adverum Biotechnologies. The company was incorporated in 2012 and is headquartered in Paris, France.

Governance aziendale

L'ISS Governance QualityScore di GenSight Biologics S.A. al 1 maggio 2024 è 10. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 10; diritti degli azionisti: 4; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.